Paper
Prostate Cancer and Prostatic Diseases (2004) 7, 111–117. doi:10.1038/sj.pcan.4500712
Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve
L C Costello1, P Feng1, B Milon1, M Tan2 and R B Franklin1
- 1Department of Biomedical Sciences, Dental School, University of Maryland, Baltimore, Maryland, USA
- 2Division of Biostatistics, Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, USA
Correspondence: LC Costello, Department of Biomedical Sciences, Dental School/University of Maryland, 666 West Baltimore Street, Baltimore, MD 21201, USA. E-mail: lcc@dental.umaryland.edu
Received 17 December 2003; Revised 22 January 2004; Accepted 2 February 2004.
Abstract
The most consistent and persistent biochemical characteristic of prostate cancer (PCa) is the marked decrease in zinc and citrate levels in the malignant cells. This relationship provides compelling evidence that the lost ability of the malignant cells to accumulate zinc is an important factor in the development and progression of prostate malignancy. In addition, this relationship provides a rational basis for the concept that restoration of high zinc levels in malignant cells could be efficacious in the treatment and prevention of PCa. Epidemiological studies regarding dietary zinc effects on PCa have been conflicting and confusing. The purpose of this presentation is to present a current state of information regarding zinc relationships in the pathogenesis and treatment of PCa. We also hope to bring more attention to the medical and research community of the critical need for concerted clinical and basic research regarding zinc and PCa.
Keywords:
zinc, prostate cancer, zinc transporters, prostate epithelial cells, apoptosis, citrate oxidation
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
